See more : Peña Verde, S.A.B. (PV.MX) Income Statement Analysis – Financial Results
Complete financial analysis of MiNK Therapeutics, Inc. (INKT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiNK Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Quantum Solutions Co.,Ltd. (2338.T) Income Statement Analysis – Financial Results
- PT Tira Austenite Tbk (TIRA.JK) Income Statement Analysis – Financial Results
- BlueRock Diamonds PLC (BRD.L) Income Statement Analysis – Financial Results
- Tian An China Investments Company Limited (TIACF) Income Statement Analysis – Financial Results
- Hyweb Technology Co., Ltd. (5212.TWO) Income Statement Analysis – Financial Results
MiNK Therapeutics, Inc. (INKT)
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.70B | 0.00 | 0.00 | 689.63K |
| Cost of Revenue | 204.62K | 30.95B | 28.36B | 55.06K | 0.00 |
| Gross Profit | -204.62K | -28.24B | -28.36B | -55.06K | 689.63K |
| Gross Profit Ratio | 0.00% | -1,044.26% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.49M | 23.12M | 13.97M | 9.51M | 19.65M |
| General & Administrative | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Other Expenses | 0.00 | 2.70M | -9.53M | -3.00M | 551.24K |
| Operating Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Cost & Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Interest Income | 463.26K | 253.32K | 2.43K | 2.44K | 1.56K |
| Interest Expense | 0.00 | 253.32K | 2.43M | 2.44M | 1.56M |
| Depreciation & Amortization | 204.62K | 121.75K | 77.96K | 55.06K | 36.82K |
| EBITDA | -22.25M | -30.83M | -27.70M | -13.74M | -22.20M |
| EBITDA Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,219.79% |
| Operating Income | -22.92M | -30.95M | -28.36M | -14.64M | -22.28M |
| Operating Income Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,231.39% |
| Total Other Income/Expenses | 463.25K | 2.96M | -1.85M | -1.60M | -1.52M |
| Income Before Tax | -22.46M | -27.99M | -30.21M | -16.24M | -23.80M |
| Income Before Tax Ratio | 0.00% | -1.03% | 0.00% | 0.00% | -3,451.46% |
| Income Tax Expense | 0.00 | -3.21M | -7.10M | -560.38K | 2.11M |
| Net Income | -22.46M | -24.78M | -23.11M | -15.68M | -25.91M |
| Net Income Ratio | 0.00% | -0.92% | 0.00% | 0.00% | -3,757.73% |
| EPS | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| EPS Diluted | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| Weighted Avg Shares Out | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
| Weighted Avg Shares Out (Dil) | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that...
MiNK Therapeutics Undervalued Given Potential Of Platform
MiNK Therapeutics reported positive results from two Phase 1 trials. Invariant Natural Killer T cells offer advantages over standard therapies.
MiNK Therapeutics, Inc. (INKT) Q3 2022 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2022 Earnings Conference Call November 2, 2022 ET Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright...
MiNK Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that...
MiNK Therapeutics, Inc.'s (INKT) CEO Jennifer Buell on Q2, 2022 Results.
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2022 Earnings Conference Call August 9, 2022 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting...
MiNK Therapeutics A Bargain For Potential Cell Therapies
iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells.
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that...
MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it...
Source: https://incomestatements.info
Category: Stock Reports